Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS-ADONIS trials.

Clin Cardiol · 2022 · PMC8799050 · PMID 35019175

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a numerical trendno p-value reported

In this posthoc analysis of the pivotal EURIDIS‐ADONIS trials, dronedarone demonstrated a significantly increased median time to first AF/AFL recurrence versus placebo in all eGFR subgroups except the most renally impaired (30–44 ml/min), where a numerical trend was observed.

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.